Table 3

Mean cognitive function in the municipality and drug groups by follow-up time point. Intention to treat analyses
Groups Moments of follow-up
Baseline, n = 180 4 months, n = 158 8 months n = 153 12 months,* n = 146 p-value1 p-value2
MMSE ± SD**
Municipality
Stimulation (n = 103) 22.9 ± 4.6 22.1 ± 5.0 22.9 ± 4.5 22.6 ± 5.2 0.15 0.017
Standard care (n = 77) 23.5 ± 4.3 23.8 ± 4. 24.4 ± 4.0 23.9 ± 4.3
Drug
Donepezil (n = 90) 23.2 ± 4.2 23.3 ± 4.5 23.8 ± 4.3 23.0 ± 4.9 0.31 0.21
Placebo n = 90 23.1 ± 4.1 22.9 ± 4.8 23.4 ± 4.3 23.3 ± 4.8
Clock Drawing Test ± SD**
Municipality
Stimulation 2.9 ± 1.2 2.9 ± 1.1 2.8 ± 1.1 3.0 ± 1.1 0.21 0.071
Standard care 2.8 ± 1.2 3.0 ± 1.2 3.1 ± 1.1 3.1 ± 1.1
Drug
Donepezil 2.9 ± 1.2 2.8 ± 1.2 2.8 ± 1.2 3.0 ± 1.0 0.56 0.26
Placebo 2.8 ± 1.1 3.0 ± 1.1 3.0 ± 1.0 3.1 ± 1.1
ADAS-cog ± SD**
Municipality
Stimulation 18.9 ± 8.7 18.5 ± 8.4 17.0 ± 9.1 16.8 ± 8.5 0.23 0.11
Standard care 17.4 ± 7.0 16.1 ± 6.9 15.7 ± 8.2 15.9 ± 8.0
Drug
Donepezil 18.6 ± 7.6 17.7 ± 7.8 16.3 ± 8.8 16.3 ± 8.4 0.59 0.24
Placebo 17.9 ± 8.4 17.1 ± 7.9 16.5 ± 8.6 16.4 ± 8.2

*n varies due to dropouts during follow-up. ** Standard deviation. p-value1 = Equal time trends between groups. p-value2 = Equal time trend between groups adjusted for baseline cognitive function.

Andersen et al.

Andersen et al. BMC Neurology 2012 12:59   doi:10.1186/1471-2377-12-59

Open Data